Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (GB:0H8T)
LSE:0H8T
Aclaris Therapeutics (0H8T) Share Price & Analysis
0 Followers
0H8T Stock Chart & Stats
Day’s Range$1.15 - $1.22
52-Week Range― - ―
Previous Close$1.25
Volume9.48K
Average Volume (3M)N/A
Market Cap
$86.53M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)N/A
BetaN/A
Next Earnings
May 08, 2024EPS Estimate
-$0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2.00Price Target Upside73.16% Upside
Rating ConsensusHold
Number of Analyst Covering2
Aclaris Therapeutics News
PremiumCompany Announcements
Board Changes Ahead of Aclaris Therapeutics Annual Meeting
PremiumCompany Announcements
Aclaris Therapeutics Executive Team Undergoes Major Changes
Bulls Say, Bears Say
Bulls Say
Drug Development ProgressThe trial's success in meeting its primary efficacy endpoint signals potential for the company's drug development.
Earnings SurpriseThe company reported a significantly smaller net loss per share than originally forecasted.
Financial StabilityThe company ended the year with a strong cash position, ensuring funding for future operations.
Bears Say
Clinical Trial FailuresACRS reported disappointing clinical readouts for their former lead program zunsemetinib in rheumatoid arthritis and hidradenitis suppurativa, failing to achieve primary and key secondary endpoints.
Strategic Business ReviewThe company will undertake a strategic review of its business following several recent clinical setbacks across its pipeline programs.
Workforce ReductionA plan to reduce its workforce by approximately 46% to reflect lower capital commitments and possible streamlining of other programs.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
13.25% Other Institutional Investors
86.75% Public Companies and
Individual Investors
0H8T FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Aclaris Therapeutics’s market cap?
Currently, no data Available
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is May 08, 2024 which is in 13 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Feb 27, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.344 by $0.324.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -$0.29.
How many shares outstanding does Aclaris Therapeutics have?
Currently, no data Available
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.344. Following the earnings report the stock price went up 3.115%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Among the largest hedge funds holding Aclaris Therapeutics’s share is Aisling Capital Management LP. It holds Aclaris Therapeutics’s shares valued at 456K.
---
Aclaris Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (73.16% Upside)
$2.00 (73.16% Upside)
Blogger Sentiment
Bullish
GB:0H8T Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $18.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-87.11%
12-Months-Change
Fundamentals
Return on Equity
-49.88%
Trailing 12-Months
Asset Growth
-22.64%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
---
0H8T Company Deck
---
0H8T Earnings Call
Q1 2023
0:00 / 0:00
---
0H8T Stock 12 Months Forecast
Average Price Target
$2.00
▲(73.16% Upside)
Technical Analysis
Aclaris Therapeutics
―
AnaptysBio
―
Apellis Pharmaceuticals
―
Arrowhead Pharmaceuticals
―
Crispr Therapeutics AG
―
Best Analysts Covering 0H8T
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-87.00%
reiterated a buy rating 9 months ago
Copying Corinne Johnson's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -87.00% per trade.
---